

Vildagliptin A Oral Treatment for Type 2 Diabetes Mellitus: A Survey Based Study.

Prof. Kiran Bibave, Sejal M Chavan, Dr. P. N Sable

SSP Shikshan Sanstha Siddhi College of Pharmacy, Chikhali, Pune, India

Abstract: *Vildagliptin is a novel oral antidiabetic medication that improves the sensitivity of pancreatic islet cells to glucose. Vildagliptin is well tolerated and effective in enhancing glyceimic control in patients with type 2 diabetes mellitus (T2DM), according to a comprehensive clinical program comprising over 22,000 patients and 7000 patient-years of exposure to the drug. Significant reductions in HbA1c have been demonstrated in monotherapy trials to be associated with body weight-neutral and lipid-neutral effects, as well as a low risk of edema and hypoglycemia. Vildagliptin is a suitable partner for combination therapy because of these qualities. Research on vildagliptin added to metformin has demonstrated notable improvements in glyceimic control (almost as well as thiazolidinedione add-on). The combination has also been shown to be well tolerated and to have minimal concerns for hypoglycemia, weight gain, or lipid abnormalities. Vildagliptin has also been shown to have good tolerability and clinically significant improvements in glyceimic control whether used as an adjunct to sulfonylurea, thiazolidinedione, or insulin treatment, or as part of an initial combination therapy with pioglitazone. Vildagliptin has been demonstrated to improve β -cell function and glyceimic management in both T2DM patients with mild hyperglycemia and people with impaired glucose tolerance; some data in the latter group suggests the drug may be able to influence the course of the disease.*

Keywords: diabetes, vildagliptin, incretin, metformin, add-on treatment, hypoglycemia